Of 41 HIV-infected patients with facial lipoatrophy who underwent autologous fat transplantation, disfiguring facial lipohypertrophy at the graft site occurred at the same time as recurrent fat accumulation at the tissue harvest site in 4 patients who had had fat transferred from the dorsocervical fat pad or from subcutaneous abdominal tissue.
Of 41 HIV-infected patients with facial lipoatrophy who underwent autologous fat transplantation, disfiguring facial lipohypertrophy at the graft site occurred at the same time as recurrent fat accumulation at the tissue harvest site in 4 patients who had had fat transferred from the dorsocervical fat pad or from subcutaneous abdominal tissue.
Lipodystrophy associated with HAART includes subcutaneous fat loss (i.e., lipoatrophy) in the face, limbs, or buttocks and/ or fat accumulation (i.e., lipohypertrophy) in the abdomen, in the breast, and/or on the dorsocervical spine (resulting in a dorsocervical fat pad or "buffalo hump") [1] . In patients with lipodystrophy, switching from treatment with either of the thymidine nucleoside analogues, stavudine or zidovudine, to treatment with the nonthymidine analogue abacavir resulted in a mild increase in peripheral fat mass; however, facial lipoatrophy did not improve [2] . The only currently available clinical interventions to treat facial lipoatrophy are fat transplantion surgery or injection with inert colloidal preparations.
Patients and methods. At our Metabolic Clinic in Modena, Italy, 41 HIV-infected patients with facial lipoatrophy underwent autologous fat transplantation to treat facial-fat wasting [3, 4] . Surgery was performed using the technique described by Coleman [3] . Intact fat-tissue parcels were harvested, and the nonviable components were removed; mechanical trauma, exposure to infectious agents, and direct contact with air were avoided to allow the graft to remain metabolically active. The graft was implanted with small cannulae in the subcutaneous space to allow nutrition and cell anchoring. The source of the graft was the subcutaneous abdominal region in 27 patients, the dorsocervical fat pad in 14 patients, the breast in 2 patients, and the pubis region in 2 patients. Few patients had multiple harvest sites as the graft source.
Results. Of the 41 patients, 32.1% were women, and 21% had Centers for Disease Control and Prevention (CDC) stage C HIV disease. At baseline, the mean values (‫ע‬SD) for clinical characteristics and laboratory values were as follows: age, years; nadir CD4 cell count, cells/mL; dura-43 ‫ע‬ 6 1 9 1 ‫ע‬ 151 tion of exposure to HAART, months; and duration of 65 ‫ע‬ 17 exposure to stavudine, months. At the time of surgery, 44 ‫ע‬ 19 the patients' mean (‫ע‬SD) CD4 cell count was cells/ 582 ‫ע‬ 248 mL, and the median HIV load was copies/mL. 9621 ‫ע‬ 24,867 Surgery resulted in a safe, effective, and durable aesthetic result in all patients, with a mean increase in the subcutaneous thickness of the cheeks of 5.5 mm ( mm). After a SD ‫ע‬ 2.4 median of 17.5 months postsurgery, 4 patients who had fat tissue harvested from a single site developed renewed fat accumulation at the harvest site. All 4 of these patients developed simultaneous facial graft hypertrophy. For 3 patients, the graft source had been the dorsocervical fat pad, and, for 1 patient, the graft source had been subcutaneous abdominal fat tissue. Patients described themselves as looking like "hamsters," because of the prominence of their cheeks.
During the follow-up period, the 4 patients had their treatment switched from stavudine to abacavir or tenofovir and from a protease inhibitor to a nonnucleoside reverse-transcriptase inhibitor or multiple nucleoside reverse-transcriptase inhibitors. None of the patients received steroids. The mean increase in body weight was 2 kg.
Progressive facial lipohypertrophy of the cheeks after surgery was documented by ultrasonography that was performed, in all cases, by the same operator with a high-frequency (7.5 MHz) transducer (3-GE Medical System; LOGIQ).
The mean increase in the subcutaneous thickness of the cheeks from the time of surgery to the evaluation at month 24 was 14.6 mm ( mm; ) in the 4 patients. Figure  SD ‫ע‬ 2.1 P p .07 1 shows the increase in the subcutaneous thickness of the cheeks in the 4 patients, compared with that of the overall cohort, and also shows the morphological appearance of patient 1.
Discussion. The reasons for fat depletion and accumulation in HIV-infected patients receiving antiretroviral therapy remain unexplained. Microscopic examination of adipocytes in patients with lipoatrophy shows remodeling that involves a combination of apoptosis, defective lipogenesis, and increased metabolic activity in different areas [5] . Antiretroviral drugs may impair lipid metabolism enzymes, which may result in hyperlipidemia, insulin resistance, and apoptosis of adipocytes, because of the great similarity between the low-density lipoprotein-receptorrelated protein and the cytoplasmic retinoic acid-binding protein type I. Several of the commonly used nucleoside analogues inhibit mitochondrial enzymes (e.g., g-polymerase), producing a progressive loss of mtDNA, with impairment of the oxidative phosphorylation pathway.
Antiretroviral drugs may cause downregulation of TNF-a homeostasis, altering transcriptional regulation, glucose levels, fatty acid metabolism, and hormone receptor signaling. Hypertrophy of the subcutaneous, denervated fat that was transplanted in the cheeks clearly suggests that the abnormal distribution of adipose tissue in HIV-infected patients cannot be entirely explained as a selective neuropathy mediated via the CNS but that some other circulating or humoral factor, as yet unknown, should be taken into account to explain the pathogenesis of HIV-associated adipose redistribution syndrome [6] .
Our observations do not provide evidence for any pathogenetic mechanism. The syndrome is unlikely to depend only on paracrine factors, such as cytokine signals. In fact, paracrine factors were present where the lipid alteration appeared, but relapse occurred in a different area. Adipocyte receptors and mitochondrial toxicity-related mechanisms could explain how receptor expression, as well as mtDNA, could be transferred from the harvest site to the graft site and remain sensitive to lipohypertrophy determinants. Another hypothesis is that lipohypertrophy of the cheeks may be the result of the expansion of brown fat that is transferred with the intervention. Ultrastructural observation suggests that dorsocervical fat consists mainly of brown fat, and its expansion has been demonstrated in areas undergoing white-fat atrophy, such as subcutaneous abdominal tissue. Our data suggests that brown fat, which has a higher mitochondria content, could be more prone to lipohypertrophy and that it may be a mechanism that compensates for fat atrophy.
The influence of genetic factors is suggested, as only a minority of the patients (21% of patients who received a graft from the dorsocervical fat pad and 4% of patients who received a graft from other sites) developed lipohypertrophy at the graft site. A clinical implication is that, when autologous fat transplantation is chosen for the treatment of facial lipoatrophy, the preferred subcutaneous harvest site should be the abdomen or pubis region.
